Pazopanib vs. Pazopanib plus Gemcitabine in patients with relapsed or metastatic uterine leiomyosarcomas or uterine carcinosarcomas: a multi-center, randomized phase-II clinical trial of the NOGGO and AGO.
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Leiomyosarcoma; Uterine cancer
- Focus Therapeutic Use
- 10 Jan 2014 New trial record